Morgan Stanley
BBIO icon

Morgan Stanley’s BridgeBio Pharma BBIO Stock Holding History

Morgan Stanley’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$126M Sell
1,693,652
-183,707
-10% -$12.9M 0.01% 1374
2026
Q1 		$139M Buy
1,877,359
+477,550
+34% +$34.6M 0.01% 1173
2025
Q4 		$107M Buy
1,399,809
+344,944
+33% +$22.6M 0.01% 1398
2025
Q3 		$54.8M Sell
1,054,865
-287,513
-21% -$14M ﹤0.01% 1935
2025
Q2 		$58M Sell
1,342,378
-156,241
-10% -$5.68M ﹤0.01% 1790
2025
Q1 		$51.8M Buy
1,498,619
+247,002
+20% +$8.33M ﹤0.01% 1788
2024
Q4 		$34.3M Sell
1,251,617
-124,125
-9% -$3.21M ﹤0.01% 2200
2024
Q3 		$35M Sell
1,375,742
-53,267
-4% -$1.4M ﹤0.01% 2208
2024
Q2 		$36.2M Buy
1,429,009
+247,115
+21% +$6.76M ﹤0.01% 2047
2024
Q1 		$36.5M Sell
1,181,894
-477,888
-29% -$16.3M ﹤0.01% 2060
2023
Q4 		$67M Buy
1,659,782
+211,722
+15% +$6.36M 0.01% 1445
2023
Q3 		$38.2M Buy
1,448,060
+894,647
+162% +$25.4M ﹤0.01% 1831
2023
Q2 		$9.52M Sell
553,413
-361,378
-40% -$5.44M ﹤0.01% 3219
2023
Q1 		$15.2M Sell
914,791
-141,046
-13% -$1.64M ﹤0.01% 2718
2022
Q4 		$8.05M Buy
1,055,837
+32,023
+3% +$307K ﹤0.01% 3285
2022
Q3 		$10.2M Sell
1,023,814
-310,646
-23% -$3.23M ﹤0.01% 2969
2022
Q2 		$12.1M Buy
1,334,460
+177,522
+15% +$1.48M ﹤0.01% 2865
2022
Q1 		$11.7M Buy
1,156,938
+762,451
+193% +$7.82M ﹤0.01% 2719
2021
Q4 		$6.58M Buy
394,487
+174,978
+80% +$7.4M ﹤0.01% 3427
2021
Q3 		$10.3M Sell
219,509
-167,909
-43% -$9M ﹤0.01% 2858
2021
Q2 		$23.6M Sell
387,418
-56,084
-13% -$3.2M ﹤0.01% 1975
2021
Q1 		$27.3M Buy
443,502
+369,317
+498% +$24.2M ﹤0.01% 1638
2020
Q4 		$5.28M Buy
74,185
+50,494
+213% +$2.44M ﹤0.01% 3198
2020
Q3 		$889K Sell
23,691
-35,826
-60% -$1.13M ﹤0.01% 4293
2020
Q2 		$1.94M Buy
59,517
+37,102
+166% +$1.13M ﹤0.01% 3629
2020
Q1 		$650K Sell
22,415
-15,855
-41% -$492K ﹤0.01% 4233
2019
Q4 		$1.34M Buy
38,270
+29,682
+346% +$823K ﹤0.01% 4331
2019
Q3 		$185K Sell
8,588
-21,112
-71% -$584K ﹤0.01% 5169
2019
Q2 		$801K Buy
+29,700
New +$810K ﹤0.01% 4349

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Morgan Stanley's BBIO Position: Q2 2026 in Review

Morgan Stanley reduced its BridgeBio Pharma (BBIO) stake by 9.8% in Q2 2026, selling an estimated $12.9M and leaving 1,693,652 shares worth $126M. The position accounts for 0.01% of the portfolio, ranked #1374.

Morgan Stanley first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. The position peaked at $139M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Morgan Stanley held 1,693,652 shares of BridgeBio Pharma worth $126M as of Q2 2026.
  • Morgan Stanley sold 183,707 BridgeBio Pharma shares in Q2 2026, an estimated $12.9M.
  • BridgeBio Pharma made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #1374 holding.
  • Morgan Stanley first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
  • Morgan Stanley's BridgeBio Pharma position peaked at $139M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.